BEPOTASTINE BESILATE (bepotastine besilate ophthalmic solution 1.5%) by Alembic is active, direct h1-receptor antagonist and an inhibitor of the release of histamine from mast cells. Approved for itching associated with signs, symptoms of allergic conjunctivitis, itching associated with allergic conjunctivitis. First approved in 2023.
Drug data last refreshed 13h ago
active, direct H1-receptor antagonist and an inhibitor of the release of histamine from mast cells.
Worked on BEPOTASTINE BESILATE at Alembic? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bioequivalence Test of "Dong-a Bepotastine Besilate Tab" and "Twolion Tab"
Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)
Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis
Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses
PK Comparisons of Bepotastine Besilate 10 mg and Bepotastine Salicylate 9.64 mg
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo